$27.23
+0.22
(+0.81%)▲
Revenue is down for the last 2 quarters, 146.26M → 15.82M (in $), with an average decrease of 89.2% per quarter
Netprofit is down for the last 2 quarters, 48.67M → -102.94M (in $), with an average decrease of 311.5% per quarter
In the last 1 year, Novo Nordisk A/s has given 283.9% return, outperforming this stock by 300.7%
In the last 3 years, Novo Nordisk A/s has given 452.1% return, outperforming this stock by 487.3%
2.61%
Downside
Day's Volatility :3.97%
Upside
1.39%
15.2%
Downside
52 Weeks Volatility :45.65%
Upside
35.9%
Period | Arrowhead Pharmaceuticals, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -23.98% | 0.0% | 0.0% |
6 Months | 9.8% | 3.0% | -0.5% |
1 Year | -16.84% | 7.2% | 0.4% |
3 Years | -35.24% | 27.5% | 19.1% |
Market Capitalization | 2.9B |
Book Value | $3.41 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.66 |
PEG Ratio | -1.32 |
Wall Street Target Price | 56.71 |
Profit Margin | -70.69% |
Operating Margin TTM | -70.45% |
Return On Assets TTM | -14.58% |
Return On Equity TTM | -43.03% |
Revenue TTM | 256.2M |
Revenue Per Share TTM | 2.41 |
Quarterly Revenue Growth YOY | -51.2% |
Gross Profit TTM | 243.2M |
EBITDA | -169.2M |
Diluted Eps TTM | -1.66 |
Quarterly Earnings Growth YOY | 0.1 |
EPS Estimate Current Year | -1.53 |
EPS Estimate Next Year | -2.77 |
EPS Estimate Current Quarter | -0.65 |
EPS Estimate Next Quarter | -0.77 |
What analysts predicted
Upside of 108.26%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 31.4M | ↑ 19736.49% |
Net Income | -34.4M | ↓ 57.93% |
Net Profit Margin | -109.46% | ↑ 51505.18% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 16.1M | ↓ 48.6% |
Net Income | -54.5M | ↑ 58.38% |
Net Profit Margin | -337.32% | ↓ 227.86% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 168.8M | ↑ 945.67% |
Net Income | 68.0M | ↓ 224.84% |
Net Profit Margin | 40.27% | ↑ 377.59% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 88.0M | ↓ 47.87% |
Net Income | -84.6M | ↓ 224.39% |
Net Profit Margin | -96.09% | ↓ 136.36% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 138.3M | ↑ 57.16% |
Net Income | -140.8M | ↑ 66.58% |
Net Profit Margin | -101.85% | ↓ 5.76% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 243.2M | ↑ 75.89% |
Net Income | -176.1M | ↑ 25.0% |
Net Profit Margin | -72.39% | ↑ 29.46% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 151.8M | ↑ 453.25% |
Net Income | 44.4M | ↓ 170.57% |
Net Profit Margin | 29.23% | ↑ 258.36% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 32.4M | ↓ 78.65% |
Net Income | -72.0M | ↓ 262.39% |
Net Profit Margin | -222.28% | ↓ 251.51% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 31.6M | ↓ 2.58% |
Net Income | -85.5M | ↑ 18.69% |
Net Profit Margin | -270.82% | ↓ 48.54% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 62.5M | ↑ 98.09% |
Net Income | -41.3M | ↓ 51.67% |
Net Profit Margin | -66.07% | ↑ 204.75% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 146.3M | ↑ 133.86% |
Net Income | 48.7M | ↓ 217.79% |
Net Profit Margin | 33.28% | ↑ 99.35% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 15.8M | ↓ 89.18% |
Net Income | -102.9M | ↓ 311.5% |
Net Profit Margin | -650.53% | ↓ 683.81% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 104.0M | ↓ 18.84% |
Total Liabilities | 23.2M | ↓ 30.16% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 111.6M | ↑ 7.29% |
Total Liabilities | 16.4M | ↓ 29.31% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 349.8M | ↑ 213.45% |
Total Liabilities | 105.8M | ↑ 546.4% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 522.5M | ↑ 49.35% |
Total Liabilities | 60.7M | ↓ 42.61% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 710.1M | ↑ 35.91% |
Total Liabilities | 301.3M | ↑ 396.22% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 691.9M | ↓ 2.56% |
Total Liabilities | 273.6M | ↓ 9.2% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 703.6M | ↑ 10.19% |
Total Liabilities | 251.3M | ↓ 5.52% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 751.8M | ↑ 6.85% |
Total Liabilities | 277.6M | ↑ 10.46% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 691.9M | ↓ 7.96% |
Total Liabilities | 273.6M | ↓ 1.44% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 891.5M | ↑ 28.84% |
Total Liabilities | 495.1M | ↑ 80.96% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 891.3M | ↓ 0.02% |
Total Liabilities | 426.2M | ↓ 13.92% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 795.9M | ↓ 10.71% |
Total Liabilities | 413.9M | ↓ 2.89% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -23.9M | ↓ 62.84% |
Investing Cash Flow | -48.6M | ↓ 461.73% |
Financing Cash Flow | 12.1M | ↓ 78.13% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -47.2M | ↑ 97.27% |
Investing Cash Flow | -7.4M | ↓ 84.72% |
Financing Cash Flow | 60.0M | ↑ 397.32% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 173.0M | ↓ 466.42% |
Investing Cash Flow | -47.7M | ↑ 542.18% |
Financing Cash Flow | 66.4M | ↑ 10.72% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -95.4M | ↓ 155.13% |
Investing Cash Flow | -240.8M | ↑ 404.29% |
Financing Cash Flow | 257.9M | ↑ 288.58% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 171.2M | ↓ 279.5% |
Investing Cash Flow | -141.7M | ↓ 41.16% |
Financing Cash Flow | 11.3M | ↓ 95.62% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -136.1M | ↓ 179.5% |
Investing Cash Flow | -5.4M | ↓ 96.18% |
Financing Cash Flow | 65.2M | ↑ 476.61% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 62.7M | ↓ 202.25% |
Investing Cash Flow | -69.8M | ↑ 108.94% |
Financing Cash Flow | 1.8M | ↓ 2.07% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -68.8M | ↓ 209.75% |
Investing Cash Flow | 61.3M | ↓ 187.85% |
Financing Cash Flow | 60.6M | ↑ 3182.77% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -68.7M | ↓ 0.26% |
Investing Cash Flow | 36.4M | ↓ 40.53% |
Financing Cash Flow | 855.0K | ↓ 98.59% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -75.5M | ↑ 9.97% |
Investing Cash Flow | -80.7M | ↓ 321.41% |
Financing Cash Flow | 250.6M | ↑ 29207.13% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -31.7M | ↓ 58.06% |
Investing Cash Flow | -36.1M | ↓ 55.31% |
Financing Cash Flow | 520.0K | ↓ 99.79% |
Sell
Neutral
Buy
Arrowhead Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Arrowhead Pharmaceuticals, Inc. | -5.82% | 9.8% | -16.84% | -35.24% | 52.0% |
![]() Moderna, Inc. | -6.8% | -31.93% | -17.68% | 49.48% | 456.61% |
![]() Regeneron Pharmaceuticals, Inc. | -1.51% | 9.46% | 21.47% | 49.65% | 113.08% |
![]() Novo Nordisk A/s | 2.45% | 158.58% | 283.85% | 452.05% | 699.12% |
![]() Seagen, Inc. | 7.08% | 3.54% | 46.23% | 15.75% | 166.19% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 16.4% | 25.65% | 33.45% | 95.64% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Arrowhead Pharmaceuticals, Inc. | NA | NA | -1.32 | -1.53 | -0.43 | -0.15 | 0.0 | 3.41 |
![]() Moderna, Inc. | 39.67 | 39.67 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 21.65 | 21.65 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 44.47 | 44.47 | 2.03 | 3.32 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.47 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 26.73 | 26.73 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Arrowhead Pharmaceuticals, Inc. | Buy | $2.9B | 52.0% | NA | -70.69% |
![]() Moderna, Inc. | Buy | $39.4B | 456.61% | 39.67 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $90.3B | 113.08% | 21.65 | 33.93% |
![]() Novo Nordisk A/s | Buy | $423.8B | 699.12% | 44.47 | 33.4% |
![]() Seagen, Inc. | Hold | $38.9B | 166.19% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.9B | 95.64% | 26.73 | 35.4% |
BlackRock Inc
Vanguard Group Inc
State Street Corporation
JPMorgan Chase & Co
FMR Inc
Amvescap Plc.
Arrowhead Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None
Read Morearrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Organization | Arrowhead Pharmaceuticals, Inc. |
Employees | 397 |
CEO | Dr. Christopher R. Anzalone Ph.D. |
Industry | Health Technology |